Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet) or Levodopa/Benserazide 100/25 mg (Madopar/Restex) and With Motor Fluctuations ("Wearing-off" Phenomenon)

Next Previous
Trial Profile

Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet) or Levodopa/Benserazide 100/25 mg (Madopar/Restex) and With Motor Fluctuations ("Wearing-off" Phenomenon)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicapone (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Bial

    • Most Recent Events

    • 07 Jan 2015 According to the ClinicalTrials.gov record the primary endpoint changed to Cmax and Tmax.
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 12 Apr 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top